The study began with the identification of the CD10 and ALDH markers through a screening and validation process (described in detail in Supplementary Data 1) in both the cisplatin-sensitive treatment-naive cancer model A2780 (Figure 1) and its long-term cisplatin-adapted counterpart A2780cis. Here, MME is linked to cancer.